Publications | Lund University Publications

1 – 8 of 8

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=author+exact+%22medk-smu%22+or+(documentType+any+%22bookEditor+conferenceEditor%22+and+editor+exact+%22medk-smu%22)&q=keywords+exact+%22pharmaceutical+industry%22&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2024
Mark Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019 : A content analysis
Larkin, James ; Matthes, Britta ; Azribi, Mohamed ; Kearns, Conor ; Mulinari, Shai ^LU ; Rickard, Emily ; Moriarty, Frank ; Fahey, Tom and Ozieranski, Piotr (2024) In Health Policy 149(November 2024).
- Contribution to journal › Article
2022
Mark Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
Ozieranski, Piotr ; Martinon, Luc ; Jachiet, Pierre-Alain and Mulinari, Shai ^LU (2022) In International Journal of Health Policy and Management 11(12). p.2842-2859
- Contribution to journal › Article
Mark A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
Ozieranski, Piotr ; Janos, Pitter ; Rickard, Emily ; Mulinari, Shai ^LU and Csanadi, Marcell (2022) In Sociology of Health & Illness 44(1). p.188-210
- Contribution to journal › Article
2021
Mark Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
Mulinari, Shai ^LU ; Davis, Courtney and Ozieranski, Piotr (2021) In Journal of White Collar and Corporate Crime 2(2). p.69-80
- Contribution to journal › Article
2020
Mark The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
Mulinari, Shai ^LU and Davis, Courtney (2020) In Social Studies of Science 50(1). p.145-169
- Contribution to journal › Article
2019
Mark Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
Richard, Emily ; Ozieranski, Piotr and Mulinari, Shai ^LU (2019) In Health Policy 123(12). p.1244-1250
- Contribution to journal › Article
2018
Mark Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
Fabbri, Alice ; Santos, Ancel.la ; Mezinska, Signe ; Mulinari, Shai ^LU and Mintzes, Barbara (2018) In International Journal of Health Policy and Management 7(6). p.504-509
- Contribution to journal › Article
2015
Mark Divergence and convergence of commercial and scientific priorities in drug development: the case of Zelmid, the first SSRI antidepressant
Mulinari, Shai ^LU (2015) In Social Science and Medicine 138. p.217-224
- Contribution to journal › Article

your query:: Remove author: Mulinari, Shai (LU); Remove keywords: pharmaceutical industry